Table 1 Demographics and clinical characteristics of patients used for the serum and urine biomarker validation studies
From: Inflammation associated anemia and ferritin as disease markers in SLE
| Â | Serum1 | Urine1 |
|---|---|---|
No. | 28 | 27 |
Female, no. (%) | 25 (89.3) | 21 (77.8) |
Age, mean +/- SE, years | 37.3 ± 1.8 | 34.6 ± 2.3 |
Race, African American/Hispanic/Caucasian, no. | 17/8/2 | 13/12/1 |
SLEDAI, median (interquartile) | 10 (3 to 16) | 10 (2 to 16) |
Renal SLEDAI, median (interquartile) | 5 (0 to 8) | 5 (0 to 8) |
No. of patients with renal SLEDAI = 0 (%) | 10 (35.7) | 9 (33.3) |
Protein:creatinine ratio, mg/mg, mean +/- SE | 2.0 ± 0.5 | 2.3 ± 0.5 |
Serum Cr, mg/dl, mean +/- SE | 1.3 ± 0.2 | 1.4 ± 0.2 |
Comorbidities, no. (%) | Â | Â |
Diabetes Melitus | 3 (10.7) | 4 (14.8) |
Hypertension | 20 (71.4) | 20 (74.1) |
Dyslipidemia | 12 (42.8) | 15 (55.6) |
Cardiovascular disease | 4 (14.3) | 3 (11.1) |
Anemia | 16 (57.1) | 18 (66.7) |
Antiphospholipid syndrome | 3 (10.7) | 3 (11.1) |
Venous thromboembolism | 3 (10.7) | 3 (11.1) |
Others | 14 (50%) | 11 (40.7) |
Current medications, no. (%) | Â | Â |
Prednisone | 17 (60.7) | 20 (74) |
Mycophenolic acid | 7 (25) | 7 (25.9) |
Cyclophosphamide | 1 (3.6) | 2 (7.4) |
Azathioprine/MTX | 6 (21.4) | 3 (11.1) |
Cyclosporine/Tacrolimus | 2 (7.1) | 1 (3.7) |
   Hydrochloroquine | 12 (42.9) | 11 (40.7) |
Angiotensin blocking agents | 14 (50) | 16 (59.3) |